Stocks and Investing
Stocks and Investing
Mon, July 23, 2012
[ 07:40 AM ] - WOPRAI
[ 05:40 AM ] - WOPRAI
[ 05:00 AM ] - Market Wire
[ 03:55 AM ] - Market Wire
[ 03:42 AM ] - WOPRAI
[ 03:42 AM ] - WOPRAI
[ 03:42 AM ] - WOPRAI
[ 03:41 AM ] - WOPRAI
[ 03:41 AM ] - WOPRAI
[ 03:41 AM ] - WOPRAI
[ 03:41 AM ] - WOPRAI
[ 03:40 AM ] - WOPRAI
[ 02:42 AM ] - WOPRAI
[ 02:41 AM ] - WOPRAI
[ 02:41 AM ] - WOPRAI
[ 02:41 AM ] - WOPRAI
[ 02:41 AM ] - WOPRAI
[ 02:40 AM ] - WOPRAI
[ 02:40 AM ] - WOPRAI
Matthew Harrison Maintained (BMRN) at Strong Buy with Increased Target to $52 on, Jul 23rd, 2012
Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Increased Target from $43 to $52 on, Jul 23rd, 2012.
Matthew has made no other calls on BMRN in the last 4 months.
There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Matthew
- Martin Auster of "UBS" Initiated at Strong Buy and Held Target at $43 on, Thursday, April 12th, 2012
- Michelle Gilson of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $43 on, Monday, March 26th, 2012